← Back

Tower Resources plc

Tower Resources plc engages in oil and gas exploration business in Africa. The company holds a 100% interest in the shallow water Thali production sharing contract that covers an area of 119.2 square kilometers located in the Rio del Rey basin, offshore Cameroon; and a 50% interest in the Algoa-Gamtoos license that covers an area of 9,369 square kilometers located in the offshore South Africa. It also holds 80% operating interest in Blocks 1910A, 1911, and 1912B covering an area of approximately 23,297 square kilometers located in offshore Namibia. The company was incorporated in 2004 and is headquartered in London, the United Kingdom.

Price · split & dividend adjusted
News & notes moving TRP.LSE
TRP.LSE

Tower Resources raises £400,000 as farm-out deals near completion

Tower Resources has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon, with both farm-out deals potentially completing as early as July. Buccaneer Energy reported an 18% rise in proved reserves in an independent review tied to its bank credit facility, with the borrowing base confirmed at $4.45 million and more growth expected as production ramps up. Light Science Technologies secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition, becoming a vertically integrated business spanning installation and material supply. Eco Buildings Group has started building a second-generation AI-enabled manufacturing line in Albania, the first major use of its recent £2.35 million fundraise, with the new line expected to be operational by the fourth quarter. Fieldwork Robotics, backed by Frontier IP Group, picked up a £300,000 investment from SEED Innovations to roll out its soft fruit harvesting robots, with multi-robot fleets potentially on farms from 2027 if trials succeed. ImmuPharma flagged new research suggesting its lead drug candidate could help treat glioblastoma, an aggressive brain cancer, while its main focus remains autoimmune disease.
Yahoo Finance·64dRead more ▾